Degenerative neurological disorders

Parkinson’s patients can be trained to respond to placebo

Placebo administration induced clinical and neuronal responses in Parkinson’s patients taking apomorphine.…

Alzheimer’s will be treated with ‘cocktail’ of drugs, predicts neuroscientist

Patients with Alzheimer’s disease will probably be treated with a cocktail of drugs in the future, a neuroscientist told the annual University College London school of pharmacy lecture at the Royal Society in central London on 12 January 2016.…

Donepezil may delay nursing home admission in moderate to severe Alzheimer’s disease

Discontinuing donepezil in Alzheimer’s patients as their disease worsens could double the risk of admission into a nursing home within a year, suggests a study published in The Lancet Neurology.…

Exposure to summer sun as a teenager could delay MS-onset

In a Danish study of people with multiple sclerosis, researchers found that the disease started later in people who had spent time in the sun every day as a teenager.…

Fears over cancer risk with MS drug cladribine unfounded

Cladribine was refused a licence for multiple sclerosis because of fears it increases the risk of cancer, but a new analysis finds no evidence to support this.…

Delayed dizziness after standing is early sign of orthostatic hypotension

Patients who have a delayed drop in blood pressure are likely to see the condition progress, which is associated with the development of neurodegenerative conditions and a 50% mortality rate.…

Brains of CJD victims show signs of Alzheimer’s pathology

Victims of Creutzfeldt–Jakob disease show evidence of Alzheimer’s pathology, suggests new research. But neuroscientists have quashed fears that people can “catch” Alzheimer’s.…

Stopping antihypertensives does not slow cognitive decline in older patients

In patients over 75 years, low blood pressure can worsen cognitive decline, but researchers found that stopping antihypertensives did not help.…

Closing in on Alzheimer’s disease

Knowledge about the neuropathology of Alzheimer’s disease has blossomed over the past few decades, leading to a better understanding of the condition and new ways to attack it.…

Data suggest that new Alzheimer’s drug solanezumab has disease-modifying properties

A monoclonal antibody in development for the treatment of Alzheimer’s disease (AD) may have disease-modifying properties, according to new research.…